In-vitro release profile of anti-periodontitis doxycycline hyclate emulsion
Periodontitis, a biofilm infection affecting the gum and teeth, has a high prevalence and has no efficient treatment to date. In this study, doxycycline hyclate, a semi synthetic derivative of tetracycline was used as the active pharmaceutical ingredient (API) to formulate an anti-periodontitis e...
| Main Authors: | , , , |
|---|---|
| Format: | Conference or Workshop Item |
| Language: | English English |
| Published: |
2017
|
| Subjects: | |
| Online Access: | http://irep.iium.edu.my/71912/ http://irep.iium.edu.my/71912/7/71912%20In-vitro%20Release%20Profile.pdf http://irep.iium.edu.my/71912/1/poster%20IABS%202017%20%281%29.pdf |
| Summary: | Periodontitis, a biofilm infection affecting the gum and teeth, has a high prevalence
and has no efficient treatment to date. In this study, doxycycline hyclate, a semi
synthetic derivative of tetracycline was used as the active pharmaceutical ingredient
(API) to formulate an anti-periodontitis emulsion. Different amount of lecithin and
hydroxypropylmethylcellulose (HPMC), both acting as surfactants, were used in the
formulations and tested for drug release profile. The in-vitro drug release profile was
conducted using USP Apparatus 1 with PBS of pH 6.8 under sink condition. A
predetermined time point h0was set up to take out the solution from the vessel for
quantification. In order to quantify the in-vitro performance, a method validation was
completed using UV-spectrophotometry following the requirements listed under ICH
Q2 (R1) guidelines. A standard calibration curve with a good linearity, R2= 0.9973 was
established. LOD and LOQ were in the range of 0.009 and 0.027 µg/mL respectively,
whereas the slope of the standard curve was 0.051. The recovery rate for intra-day
was from 98.27 to 101.39%, and from 100.85 to 102.57% for inter-day. The RSD was
1.6. It was found that lecithin-added formulation showsed complete drug release after
5 hours. In contrast, lecithin+HPMC-added formulation gave a total release after 2
hours. Thus, the lecithin-added formulation showed a slower release profile compared
to the lecithin+HPMC-added formulation and may be the formulation of choice for
future testings. |
|---|